Jcog9511
Web13 dic 2013 · In contrast, the dose intensity of irinotecan (60 mg/m 2, Days 1, 8 and 15, every 4 weeks) was 45 mg/m 2 /week in JCOG9511. However, the omission of Day 15 irinotecan occurred in 50% of the courses in JCOG9511 . WebDownload scientific diagram Phase III Study of CPT-11/CDD vs VP-16/CDDP in SCLC (JCOG9511). from publication: Progress in treatment of small-cell lung cancer: Role of CPT-11 Small-cell lung ...
Jcog9511
Did you know?
WebWe thank Nobuyuki Horita and colleagues for their interest in the updated results of the CASPIAN trial.1 We believe that the platinum–etoposide chemotherapy regimen used in CASPIAN was appropriate. Major oncological treatment guidelines worldwide recommend either cisplatin or carboplatin, combined with etoposide, as the standard first-line … Web(JCOG9511). Proc Annu Meet Am Soc Clin Oncol. 2000;19:1887. Abstract. Compared to cisplatin plus etoposide, the current standard approach for extensive-stage small-cell lung cancer,cisplatin and CPT-11 showed a significant improve-ment in median survival (420 days vs 300 days). If these data are con-firmed, cisplatin and CPT-11 may
Web3 dic 2013 · (JCOG9511) comparing irinotecan plus cisplatin versus etoposide plus cisplatin for extensive-stage SCLC. Median overall survival was 12·8 months and 19·5% patients were alive at 2 years in the irinotecan plus cisplatin group, whereas in the etoposide plus cisplatin group, median overall survival was 9·4 months only 5·2% of patients were alive … Web1 gen 2014 · The doses of cisplatin were the same as in the previous JCOG trial (JCOG9511) in extensive-stage SCLC. 9 If the leucocyte count decreased to less than 3000 leucocytes per μL or the platelet count fell below 10 5 platelets per μL on the first day of etoposide plus cisplatin or irinotecan plus cisplatin, chemotherapy was withheld until the …
Webundertook a randomised phase 3 trial9 (JCOG9511) comparing irinotecan plus cisplatin with etoposide plus cisplatin in patients with extensive-stage SCLC. Response and overall survival were signifi cantly better for patients treated with irinotecan than those treated with etoposide. The result prompted us to explore the use of irinotecan WebJCOG9511 trial (2002) showed longer overall survival in Japanese patients treated with cisplatin–irinotecan than in patients treated with cisplatin–etoposide (12·8 months . vs. 9·4 months, p=0·002). 3. However, oncologists in Europe and in the USA did not accept cisplatin–irinotecan as a standard regimen because the results of JCOG9511 ...
Web10 ago 2024 · JCOG previously reported the results of a randomized phase III trial (JCOG9511). They found that irinotecan, an inhibitor of the nuclear enzyme topoisomerase I, could improve OS and PFS when combined with platinum. Nevertheless, a series of studies conducted in America and Europe failed to confirm these positive results …
Web3 nov 2012 · In the JCOG9511 study , grade 3 to 4 diarrhea occurred in 16.0 % of patients treated with cisplatin plus CPT, whereas there was 8.0 % in the present study. Two patients who developed grade 3 diarrhea were switched to the cisplatin plus etoposide regimen and were able to receive a total of 4 cycles of first-line chemotherapy. brake distance chartWebJCOG9511 (phaseIII) 進展型小細胞肺癌（ED-SCLC）に対する塩酸イリノテカン＋シスプラチンとエトポシド＋シスプラチンの第Ⅲ相無作為化比較試験 研究グループ braked kitchen trolleyWebHome Printers Home Printers Home Printers. Functional and stylish home photo printers and all-in-ones delivering quality results. Small Office Printers Small Office Printers Small Office Printers. Get productive with a range of small … braked jockey wheelWeb3 dic 2013 · (JCOG9511) comparing irinotecan plus cisplatin versus etoposide plus cisplatin for extensive-stage SCLC. Median overall survival was 12·8 months and 19·5% patients were alive at 2 years in the irinotecan plus cisplatin group, whereas in the etoposide plus cisplatin group, median overall survival was 9·4 months only 5·2% of patients were alive … brake distribution block problemsWeb2 mar 2024 · We read with great interest the Article by Jonathan Goldman and colleagues1 regarding the updated data from the CASPIAN trial. The combination of a PD-L1 inhibitor plus platinum–etoposide has been suggested for the first-line treatment of extensive-disease small-cell lung cancer.1,2 However, we have a concern about the standard regimen of … braked lightweight car trailerWeb験（JCOG9511）が実施4され，生存期間中央値（median overallsurvival；mOS）はPE療法が9.4か月であった のに対しPI療法では12.8か月と有意な延長を認めた． この結果から，国内における標準治療はPI療法であると 考えられる．しかしながら，JCOG9511を追試 … hafal actsWebThe New England Journal of Medicine: Research & Review Articles on ... brake distribution block ford